Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Gains from Investment Securities (2017 - 2025)

Nutex Health's Gains from Investment Securities history spans 11 years, with the latest figure at $1.4 million for Q1 2025.

  • For Q1 2025, Gains from Investment Securities changed N/A year-over-year to $1.4 million; the TTM value through Mar 2025 reached $2.5 million, changed N/A, while the annual FY2024 figure was $2.7 million, 23.52% down from the prior year.
  • Gains from Investment Securities for Q1 2025 was $1.4 million at Nutex Health, up from $741222.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.5 million in Q1 2022 and bottomed at $741222.0 in Q4 2024.
  • The 4-year median for Gains from Investment Securities is $1.4 million (2025), against an average of $2.4 million.
  • The largest YoY upside for Gains from Investment Securities was 585.54% in 2021 against a maximum downside of 8.34% in 2021.
  • A 4-year view of Gains from Investment Securities shows it stood at $2.9 million in 2021, then soared by 126.01% to $6.5 million in 2022, then tumbled by 88.6% to $741222.0 in 2024, then soared by 84.43% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Gains from Investment Securities are $1.4 million (Q1 2025), $741222.0 (Q4 2024), and $6.5 million (Q1 2022).